ライフサイエンスコーパス: glucose tolerance test

1 ulin extraction from a mixed-meal or an oral glucose tolerance test).

2 est (e.g., a glucose clamp or an intravenous glucose tolerance test).

3 mia (glucose area under the curve in an oral-glucose-tolerance test).

4 ulin-modified frequently sampled intravenous glucose tolerance test.

5 ucose tolerance after oral dosing in an oral glucose tolerance test.

6 e measures assessed by using a standard oral glucose tolerance test.

7 ucose) in the basal state and during an oral glucose tolerance test.

8 Insulin sensitivity was assessed by oral glucose tolerance test.

9 nimals were then subjected to an intravenous glucose tolerance test.

10 SI was determined by intravenous glucose tolerance test.

11 d 629 women, respectively, completed an oral glucose tolerance test.

12 nofixation, fasting glucose measurement, and glucose tolerance test.

13 sulin sensitivity as measured by intravenous glucose tolerance test.

14 ration also increases in response to an oral glucose tolerance test.

15 vels and continued through a 3-h intravenous glucose tolerance test.

16 sured using the insulin-modified intravenous glucose tolerance test.

17 istance was confirmed through an intravenous glucose tolerance test.

18 derived from frequently sampled intravenous glucose tolerance test.

19 impaired fasting glucose determined by oral glucose tolerance test.

20 concentrations were measured during an oral glucose tolerance test.

21 lin secretion was measured by an intravenous glucose tolerance test.

22 blood glucose test, and a confirmatory oral glucose tolerance test.

23 ion for blood and urine sampling and an oral glucose tolerance test.

24 underwent hemoglobin A1c testing and an oral glucose tolerance test.

25 after surgery, as assessed by an intravenous glucose tolerance test.

26 phenotypes were derived from a 5-point oral glucose tolerance test.

27 al of diabetes; mice were then given an oral glucose tolerance test.

28 nd 2-hour glucose was measured after an oral glucose tolerance test.

29 men with type 2 diabetes before and after a glucose tolerance test.

30 ose homeostasis measured by means of an oral glucose tolerance test.

31 sed by using the Matsuda method from an oral-glucose-tolerance test.

32 by nonfasting blood glucose measurements and glucose tolerance tests.

33 ic-euglycemic clamp and intravenous and oral glucose tolerance tests.

34 reatment using both the oral and intravenous glucose tolerance tests.

35 mumol/L v 131.7 mumol/L; P = 0.09), and oral glucose tolerance tests.

36 aset acquired from human subjects undergoing glucose tolerance tests.

37 tolerance was evaluated with intraperitoneal glucose tolerance tests.

38 betes, restoring a physiological response to glucose tolerance tests.

39 d 53 controls underwent oral and intravenous glucose tolerance tests.

40 Insulin kinetics were calculated from oral glucose tolerance tests.

41 Diabetes status was assessed by using oral-glucose-tolerance tests.

42 Participants were diagnosed by 75 g oral glucose-tolerance tests.

43 der the curve for glucose during 2-hour oral glucose tolerance testing.

44 r beta-cell function, which was evaluated by glucose tolerance testing.

45 tion index (DI) were assessed by intravenous glucose tolerance testing.

46 The latter is detected by oral glucose tolerance testing.

47 ned glucose intolerant as determined by oral glucose tolerance testing.

48 was measured by nonfasting blood glucose and glucose tolerance testing.

49 d IR in the obese subjects was documented by glucose tolerance testing.

50 normal/five abnormal glucose tolerance (oral glucose tolerance test 1-h glucose >=155 and 2-h glucose

51 a, preferred strategies were the 2-hour oral glucose tolerance test (100% effectiveness; $390 per cas

52 After 6 wk, a 75-g oral-glucose-tolerance test (13C-labeled) and a subsequent fa

53 f 1319 people who were screened with an oral glucose tolerance test, 196 (15%) had impaired glucose t

54 cose during the first 30 minutes of the oral glucose tolerance test 2 years later.

55 linemia (insulin area under the curve during glucose tolerance test 609 +/- 103 vs. 313 +/- 66 ng mL(

56 ntagonist exendin(9-39)NH(2) During 4-h oral glucose tolerance tests (75 g) combined with an ad libit

57 All underwent an oral glucose tolerance test, a liver panel, and a lipid profi

58 ulin area under the curve (AUC) from an oral glucose tolerance test, aerobic fitness (peak oxygen con

59 ning in the early postpartum period via oral glucose tolerance testing after GDM, which is a time-con

60 rve of insulin and glucose after a 75-g oral-glucose-tolerance test after 4 mo of treatment.

61 nd glucose disappearance rate on intravenous glucose tolerance test, all of which worsened minimally

62 ng blood glucose concentrations and 2-h oral glucose tolerance tests among a cross-section of adults

63 curve for glucose, and insulin from an oral glucose tolerance test) analysed in the intention-to-tre

64 d 10 healthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglycemic i

65 ual intravenous [6,6-2H2]-, oral 13C-labeled glucose tolerance test and a polysomnographic recording

66 nnaire, color Doppler echocardiography, oral glucose tolerance test and blood biomarkers analyses wer

67 the suppression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin infusio

68 gestational diabetes (diagnosed with an oral glucose tolerance test and by criteria from the Internat

69 on not only improved the response to an oral glucose tolerance test and corrected insulin signaling b

70 All underwent an oral glucose tolerance test and fasting lipoprotein subclasse

71 ion using the frequently sampled intravenous glucose tolerance test and insulin sensitivity using the

72 A glucose tolerance test and insulin tolerance test showed

73 in sensitivity, as insulin levels during the glucose tolerance test and insulin, leptin, and adiponec

74 d disposition index were measured after oral glucose tolerance test and isoglycemic IV glucose inject

75 ), which were determined from an intravenous glucose tolerance test and minimal modeling.

76 All participants underwent a standard oral glucose tolerance test and provided detailed clinical, s

77 Participants underwent an oral glucose tolerance test and retinal imaging at 26-28 week

78 amily history of T2DM (FH+) received an oral glucose tolerance test and two-step hyperglycemic clamp

79 cose during the first 30 minutes of the oral glucose tolerance test and using the area under the curv

80 ecipients without diabetes underwent an oral glucose tolerance test and were observed until primary o

81 e and after beta3-AR agonist treatment, oral glucose tolerance tests and euglycemic clamps were perfo

82 inemia, by combining microdialysis with oral glucose tolerance tests and euglycemic-hyperinsulinemic

83 t blockade of insulin secretion were used in glucose tolerance tests and in positron emission tomogra

84 hanced suppression of plasma FFA during oral glucose tolerance tests and insulin clamp in obese NGT a

85 Metabolism investigations showed abnormal glucose tolerance tests and low HDL values in some patie

86 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test

87 the glucose area under the curve in an oral glucose tolerance test, and AcAc predicted the conversio

88 ose and lipid levels, the results of an oral glucose tolerance test, and blood pressure were used to

89 on (O-BP) using a clinical examination, oral glucose tolerance test, and gene expression and DNA meth

90 and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell func

91 clinical laboratory testing, including oral glucose tolerance test, and ultrasonographic investigati

92 ulin and glucagon concentrations during oral glucose tolerance test, and, in vitro, by measuring gluc

93 questionnaires, clinical measurements, oral glucose tolerance tests, and laboratory examinations wer

94 by nuclear magnetic resonance spectroscopy, glucose tolerance tests, and plasma analyses.

95 We used fasting plasma glucose, glucose tolerance tests, and self-reported diabetes diag

96 asting blood glucose measurement, a 2-h oral-glucose-tolerance test, and record linkage to a reimburs

97 p with measurement of glucose turnover; oral glucose tolerance test; and a liver biopsy.

98 lucose and insulin during an intraperitoneal glucose tolerance test; and Glut4 and ApoE expression in

99 for 2 years that included 2-hour, 75-g oral glucose tolerance testing; anthropometry; and interviews

100 According to oral glucose tolerance testing, approximately 14% of patients

101 diate hyperglycaemia defined without an oral glucose tolerance test as impaired fasting glucose (IFG)

102 sulting in impaired insulin secretion during glucose tolerance tests as well as hyperglycemic clamps.

103 maternal metabolism obtained during an oral glucose tolerance test at approximately 28 weeks' gestat

104 Participants underwent an oral glucose tolerance test at baseline and after 2 years to

105 body surface area burned, underwent an oral glucose tolerance test at discharge.

106 and insulin will be measured during an oral glucose tolerance test at weeks 0 and 12.

107 Glucose tolerance testing at discharge offers an opportu

108 Oral glucose tolerance tests at baseline and after 1 year of

109 in, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end.

110 Oral glucose tolerance tests at discharge revealed that metfo

111 ellitus (GDM) during pregnancy from clinical glucose tolerance tests at median 28.1 weeks gestation.

112 All women underwent 75-g oral glucose tolerance tests at ~26 weeks of gestation; we us

113 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals.

114 nsulin, and C-peptide measured by using oral-glucose-tolerance tests at the end of each diet.

115 RSM with three predonation RFs (oral glucose tolerance test, basal insulin, fasting plasma gl

116 assessment of insulin resistance and an oral glucose tolerance test-based index (Matsuda insulin sens

117 euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin resista

118 ce, they were less hyperinsulinemic during a glucose tolerance test because of reduced insulin secret

119 SG or RYGB were studied with an intravenous glucose tolerance test before surgery and at 5-12% weigh

120 Participants also underwent glucose tolerance tests before and after intervention.

121 e measures were difference in change in oral glucose tolerance test between the groups and between ba

122 ered questionnaires, by fasting and 2-h oral-glucose-tolerance test blood glucose measurement at re-e

123 ered questionnaires; by fasting and 2-h oral-glucose-tolerance-test blood glucose measurement at re-e

124 d aSAT, S(I) (frequently sampled intravenous glucose tolerance test), body composition (dual-energy X

125 ecognition is crucial, and the modified oral glucose tolerance test, but not gastric emptying testing

126 glucose (beta = 0.46, P = 0.00090) post oral glucose tolerance test, but only the latter passed Bonfe

127 In vivo, the intravenous glucose tolerance test characterized oxyntomodulin-induc

128 The glucose tolerance test clarified that the complex retain

129 exhibited fasting hyperglycemia and impaired glucose tolerance test compared with wild-type mice.

130 ipose tissue biopsies were obtained and oral glucose tolerance tests conducted.

131 CBV at rest and during an intravenous glucose tolerance test demonstrated a sustained increase

132 Glucose tolerance tests demonstrated that ATGL knockdown

133 In the independent cohort, only oral glucose tolerance test-derived indexes were associated w

134 glucose, fasting glucose or insulin, or oral glucose tolerance test-derived measures.

135 glucose area under the curve on 2-hour oral glucose tolerance test differed across arms (1-way ANCOV

136 sulin sensitivity, show improvements in oral glucose tolerance tests, display reduced adipose tissue

137 ongitudinal cohort of women with GDM who had glucose tolerance tested during the early postpartum per

138 levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, i

139 levels, plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, i

140 asured by the frequently sampled intravenous glucose tolerance test (four cohorts) or euglycemic clam

141 ange in SI by frequently sampled intravenous glucose tolerance test from entry to week 12.

142 ubmitted to a frequently sampled intravenous glucose tolerance test (FSIGT) with the stimulator on an

143 lin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated hepatic ver

144 e STM and by frequently sampling intravenous glucose tolerance test (FSIVGTT).

145 ulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT).

146 ere glucose tolerance (measured with an oral glucose tolerance test given after 90 min) and meal size

147 eostasis model assessment, and 2-h post-oral glucose tolerance test glucose and insulin levels.

148 During glucose tolerance tests, glucose disposal was enhanced i

149 object recognition, grip strength, rotarod, glucose tolerance test (GTT) and insulin tolerance test

150 Epm2a-/- mice and observed no differences in glucose tolerance tests (GTTs) or insulin tolerance test

151 asma glucose >/=200 mg/dL during a 75-g oral glucose tolerance test had a definite diagnosis of type

152 orrelated with glucose responses during oral glucose tolerance testing, HbA1c, beta-cell function, an

153 = .03), plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to

154 g or non-fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and/or a

155 olerance during oral but not intraperitoneal glucose tolerance tests, highlighting the involvement of

156 test (GCT) followed by a 75-gram 2-hour oral glucose tolerance test if GCT result was >/=7.8 mmol/L.

157 ield test, ABA paradigm, and intraperitoneal glucose tolerance test (IGTT).

158 In the oral glucose tolerance test, IL-1betaAb-treated CDs-HSD rats

159 identify high risk women for subsequent oral glucose tolerance testing improves dysglycemia detection

160 Nemos) with sham stimulation during an oral glucose tolerance test in a randomized, single-blind, cr

161 s system activity at rest and during an oral glucose tolerance test in obese metabolic syndrome (MetS

162 ed plasma GLP-1 concentration during an oral glucose tolerance test in rats.

163 d half-life and glucose tolerance in an oral glucose tolerance test in rodents.

164 ulin stainings and performed intraperitoneal glucose tolerance testing in transgenic mice overexpress

165 emonstrated blood glucose reductions in oral glucose tolerance tests in both C57BL/6J mice and high-f

166 d intraperitoneal sensors during intravenous glucose tolerance tests in eight swine.

167 orated glucose excursions in intraperitoneal glucose tolerance tests in mice with streptozotocin-indu

168 tance and sensitivity were defined from oral-glucose-tolerance tests in 86 overweight and obese subje

169 bited lower fasting glucose levels, improved glucose tolerance test, increased lactate levels, reduce

170 and developed systemic insulin resistance in glucose tolerance tests, insulin tolerance tests, and hy

171 diac structure and function, intraperitoneal glucose tolerance test (IPGTT) for glucose metabolism, i

172 and subsequently assessed by intraperitoneal glucose tolerance test (IPGTT).

173 lin concentrations during an intraperitoneal glucose tolerance test (ipGTT).

174 erance was measured using an intraperitoneal glucose tolerance test (IPGTT).

175 blood glucose measurements, intraperitoneal glucose tolerance testing (IPGTT), and human C-peptide s

176 Intravenous glucose tolerance test IVGTT and OGTT insulin secretion

177 hyperinsulinemic clamp (EHC), by intravenous glucose tolerance test (IVGTT) and by oral glucose toler

178 nd minimal model analysis of the intravenous glucose tolerance test (IVGTT) to document progression o

179 ose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performed between th

180 tion in humans during an in-vivo Intravenous Glucose Tolerance Test (IVGTT).

181 ation of glucose disposal during intravenous glucose tolerance tests (IVGTT) remains critical for str

182 esponses to intravenous (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-po

183 into the third ventricle during intravenous glucose tolerance tests (IVGTTs).

184 mps), and insulin secretion [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four participant

185 On the basis of the glucose tolerance test known to be a clinically relevant

186 of glucose and insulin levels during an oral glucose tolerance test; levels of low-density lipoprotei

187 Frequently sampled intravenous-glucose-tolerance tests measured insulin sensitivity (SI

188 Oral glucose tolerance tests, mixed-meal tolerance tests, and

189 llenge glucose levels were assessed during a glucose tolerance test (n = 2,264).

190 g to identifying IGT/NODAT using 2-hour oral glucose tolerance test (n = 66), fructosamine was the mo

191 wmetry), and glucose metabolism status (oral glucose tolerance test; normal glucose metabolism [n=126

192 A 2-hour oral glucose tolerance test of >=140 mg/dL remains the most c

193 Plasma samples from intravenous glucose tolerance tests of 2.5- and 5-month-old GIPR(dn)

194 uding results of a 26-28 week gestation oral glucose tolerance test) of women from the Born in Bradfo

195 insulin-clamp (40 mU/m(2) . min) and an oral glucose tolerance test (OGTT) (75 g) on separate days.

196 from prediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measurement ov

197 d women aged 50-65 were subjected to an oral glucose tolerance test (OGTT) and a mixed-meal test (MMT

198 In this prospective clinical study, an oral glucose tolerance test (OGTT) and an intravenous glucose

199 d beta-cell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic intrave

200 h varying glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insulin cla

201 , hemoglobin A1C, body composition, the oral glucose tolerance test (oGTT) and the Sweet Taste Test (

202 tracer and labeled glucose infusion and oral glucose tolerance test (OGTT) before and 6 months after

203 glucose beverage consumption during an oral glucose tolerance test (OGTT) for 400 northern European

204 (GDM) is conventionally confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of gesta

205 s glucose tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessions.

206 luation of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based popul

207 compound that displayed activity in an oral glucose tolerance test (OGTT) in normal and diabetic mic

208 ained, in addition to 0-hour and 2-hour oral glucose tolerance test (OGTT) results, with measurement

209 We analyzed the results of an oral glucose tolerance test (OGTT) routinely performed before

210 itive O'Sullivan test (POT) results, an oral glucose tolerance test (OGTT) was performed to diagnose

211 An oral glucose tolerance test (OGTT) was used to evaluate gluco

212 f glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individua

213 d control participants and underwent an oral glucose tolerance test (OGTT), a hypoglycemia questionna

214 Diagnosis is usually performed using an oral glucose tolerance test (OGTT), although a non-fasting, g

215 educing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost

216 blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between th

217 ted controls were evaluated using a 2-h oral glucose tolerance test (OGTT), with 7 samples of plasma

218 Herein we describe oral glucose tolerance test (OGTT)-modeled beta-cell function

219 placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).

220 = 11.1 mmol/L (>/= 200 mg/dL) during an oral glucose tolerance test (OGTT).

221 fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).

222 e-lowering actions were tested after an oral glucose tolerance test (OGTT).

223 lin required to clear glucose during an oral glucose tolerance test (OGTT).

224 of beta-cell function derived from the oral glucose tolerance test (OGTT).

225 k diabetes based on the rarely utilized oral glucose tolerance test (OGTT).

226 At wk 15, pigs were subjected to an oral glucose tolerance test (OGTT); blood glucose increased (

227 ge at delivery, parity, maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for Mode

228 Oral glucose tolerance testing (OGTT) has been mooted as an a

229 c renal transplant recipients underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (baseline

230 r death and who had undergone 2 or more oral glucose tolerance tests (OGTT) using grouped analyses an

231 acodynamic endpoints were explored with oral glucose tolerance tests (OGTT), serum lipid profiles, ma

232 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-eugly

233 273), and whose mothers had a 2-h 75-g oral-glucose-tolerance test (OGTT) at 26-28 weeks of gestatio

234 )) of 22.4 +/- 0.8 were subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days with th

235 At each visit, an oral-glucose-tolerance test (OGTT) was performed.

236 etone monoester (KE) drink before a 2-h oral-glucose-tolerance test (OGTT) would lower blood glucose

237 Postinfusion, a 240-min oral-glucose-tolerance test (OGTT; 75 g) was administered.

238 n research visits including 2-hour 75-g oral glucose tolerance tests (OGTTs) at study baseline (6-9 w

239 postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that high

240 zing antibody was administered prior to oral glucose tolerance tests (OGTTs).

241 sures collected from frequently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29 recru

242 se metabolism observed in an intraperitoneal glucose tolerance test on male C57BL/6J mice supported t

243 ues in response to a glucose load applied in glucose tolerance tests on different days, promoted gluc

244 function, we performed oral and intravenous glucose tolerance tests on mutation carriers and matched

245 erum insulin; HbA1c; glucose dynamics during glucose tolerance testing; or in pancreatic islet area o

246 or a reduced insulinemic response to an oral-glucose-tolerance test over time with daily breakfast re

247 During the oral glucose tolerance test, overfeeding significantly increa

248 mption (P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10) trended toward being l

249 with improved insulin response after an oral glucose-tolerance test (P = 9.8 x 10(-5)), whereas abnor

250 Intravenous glucose tolerance tests performed at 1, 2, and 3 or more

251 All underwent oral glucose tolerance tests pre-LTx and serially post-LTx.

252 ter of pregnancy (2-h glucose after the oral glucose tolerance test; r(s) </= -0.21, P < 0.05).

253 n glucose tolerance estimated by a 75-g oral glucose tolerance test result.

254 HFD worsened glucose tolerance test results and caused increased adip

255 ocyte size; for mice on an HFD, SAP improved glucose tolerance test results and reduced adipocyte siz

256 ormoglycemic throughout the study, and their glucose tolerance test results were similar to control C

257 On the basis of oral glucose tolerance test results, participants were groupe

258 assessed by a frequently sampled intravenous glucose tolerance test.RESULTSChronic mirabegron therapy

259 Finally, an intravenous glucose tolerance test revealed higher insulin sensitivi

260 In addition, body weight records and a glucose tolerance test revealed no differences between W

261 s by hyperinsulinemic-euglycemic clamp and a glucose tolerance test revealed no differences in insuli

262 Hyperglycemic-euglycemic clamp studies and glucose tolerance testing revealed insulin resistance.

263 Oral glucose tolerance tests revealed that male Znt7 KO mice

264 The glucose tolerance test showed major improvement of the g

265 ta obtained during a frequently sampled i.v. glucose tolerance test showed that the antidiabetic effe

266 Glucose tolerance tests showed that Syn-1A-betaKO mice e

267 irst-phase insulin release on an intravenous glucose tolerance test that was higher than the threshol

268 s score was combined with results of an oral glucose tolerance test, the AUC reached 82.4% (80.9-83.9

269 In the oral glucose tolerance test, the chloroform extract exerted t

270 in adults and frequently sampled intravenous glucose tolerance tests using Bergman minimal model in c

271 nsulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals w

272 times (<4.2 min) in response to intravenous glucose tolerance tests versus burst NO-releasing and co

273 An oral glucose tolerance test was administered at discharge.

274 ulin resistance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.

275 Oral glucose tolerance test was considered the gold standard

276 Intravenous glucose tolerance test was performed at baseline and at

277 Oral glucose tolerance test was performed within 2 weeks afte

278 A frequently sampled intravenous glucose tolerance test was used to obtain precise measur

279 An oral-glucose-tolerance test was performed pre- and postinterv

280 itivity and rate sensitivity during the oral glucose tolerance test were measured with the model by M

281 sulinemic-euglycemic clamp and a 3-hour oral glucose tolerance test were performed to evaluate insuli

282 ulinemic-euglycemic clamp and an intravenous glucose tolerance test were performed.

283 oid hormone, vitamin D, and response to oral glucose tolerance testing were similar.

284 Oral glucose tolerance tests were administered at the same ti

285 mples were collected in the morning and oral glucose tolerance tests were done in accordance with a s

286 Intravenous glucose tolerance tests were performed 2 weeks after sur

287 Physical examinations and oral glucose tolerance tests were performed at baseline and a

288 Frequently sampled intravenous glucose tolerance tests were performed before and after

289 etric parameters and frequently sampled oral glucose tolerance tests were performed before and after

290 Intravenous glucose tolerance tests were performed before and after

291 Insulin and glucose tolerance tests were undertaken and hepatic AMPK

292 clearance were estimated by means of an oral glucose tolerance test, whereas peripheral insulin sensi

293 able to KC islet grafts, postintrapertioneal glucose tolerance testing, whereas SC recipients remaine

294 ol participants underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood samp

295 total of 1,437 individuals underwent an oral glucose tolerance test with measurements of circulating

296 FLD patients underwent liver biopsy, an oral glucose tolerance test with minimal model analysis to yi

297 in, 30 min before and during the entire oral glucose tolerance test with stimulation cycles of 30 s o

298 Oral glucose tolerance testing with glucose, insulin, and C-p

299 In oral glucose tolerance tests with diet-induced obese mice, NT

300 D patients underwent a liver biopsy, an oral-glucose-tolerance test with minimal model analysis of gl